• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Diagnostic tools
      • Research team
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

Michael Schultze

Director of Real-World Evidence & Safety Data Analytics

Foto - Michael Schultze

Dr. Michael Schultze leads a dedicated team of Real-World Evidence (RWE) experts in designing and implementing secondary data-driven non-interventional studies.

Alongside his managerial responsibilities for the RWE secondary data department, Michael is responsible for the development of medical algorithms and the interpreting of big medical data sets of secondary data projects. These projects cover diverse topics such as Epidemiology, HEOR and Safety, and a broad range of therapy areas.

His interdisciplinary experience combines the three areas of expertise essential for secondary data-related studies: medical expertise, advanced project management skills, and a profound understanding of working with Real-World Data (RWD). With his in-depth knowledge of current opportunities, challenges, needs, and limitations of RWE and RWD, Michael is also ideally placed to consult regarding RWE in general and different study designs to bridge the growing need for leading-edge secondary data methodologies with classical post-authorization safety and efficacy studies.

Michael holds a doctorate and a state examination degree in Veterinary Medicine, both from the Ludwig Maximilian University of Munich, Germany.

  • share 
  • tweet 
  • share 
  • share 

Publications

N Hunnicutt Jake, Schultze Michael, Garal-Pantaler Elena, Pignot Marc, Georgiou Mary Elizabeth, Gairy Kerry, Prevalence of lupus nephritis among patients with systemic lupus erythematosus in Germany Nephrology Dialysis Transplantation, Volume 37, Issue Supplement_3, May. 2022; 10.1093/ndt/gfac071.036.
Schultze Michael, Zema C., Carroll R., Hurst M., Borchert J., Zhong Y., Krause T., Bluhmki T., Partington H., Population estimates of obstructive and non-obstructive hypertrophic cardiomyopathy in the UK and Germany. 2022;
Sedaghat-Hamedani F., Zema C., Schultze Michael, Borchert J., Zhong Y., Bluhmki T., Krause T., Schmoelders J., Meder B., Clinical and economic burden of hypertrophic obstructive cardiomyopathy in Germany DGK Herztage 29.09 – 01.10.2022. 2022; 10.1007/s00392-022-02087-y.
Schultze Michael, Garal-Pantaler Elena, Pignot Marc, Carnarius H., Gairy Kerry, Levy R., Economic Burden of Organ Damage in Systemic Lupus Erythematosus: Results From a German Claims Analysis. DGRh Kongress. 2021; 10.3205/21dgrh064.
Schultze Michael, Garal-Pantaler Elena, Pignot Marc, Carnarius H., Levy R., Gairy Kerry, The Burden of Organ Damage Among Patients With Systemic Lupus Erythematosus in Germany. International Congress on Systemic Lupus Erythematosus. LUPUS & CORA 2021. 2021;
Kossack Nils, Schoenfelder T., Schultze Michael, Pignot Marc, Mehta S., Nazareth T., Walzer S., Real-World Cost Difference in Patients With Psoriasis Initiating Apremilast vs. Secukinumab After Conventional Systemic Therapy Using German Sickness Fund Data DDK KOMPAKT 2020. JDDG Volume 18 Issue S1. 2020. 2020; 10.1111/ddg.14021.
Kossack Nils, Schoenfelder T., Schultze Michael, Pignot Marc, Mehta S., Nazareth T., Walzer S., Real-World Cost Difference in Patients with Psoriasis Newly Initiating Apremilast vs. Biologic Treatment after Conventional Systemic Therapy: A Retrospective Analysis of German Sickness Fund Data. Value in Health (22). 2019; 10.1016/j.jval.2019.09.2645.

sidebar

Executive Team

  • Clare Barnett
  • Karl Pauls
  • Michael Schultze
  • Alfred Pauls
  • Anja Bauerfeind
  • Do Minh Thai
  • Elisabeth Finger
  • Jens A. Lange

Management Board

  • Klaas Heinemann
  • Clare Barnett
  • Marc Pignot
  • Karl Pauls
  • Johanna Poppe

Project Management Team

  • Pauline De Corte
  • Lisa Eggebrecht
  • Maria Cabral
  • Anitha Pitchika
  • Mohammed Dagher

Search

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Expertise

  • Real-World Evidence
  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Diagnostic tools
  • Data collection instruments

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2023 ZEG Berlin

Impressum

Website by Laura Yeffeth.